Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: April 29, 2022 Report Code: GMDGDHC22131IDB-ST

Select Item

Severe Acute Respiratory Syndrome Pipeline Drugs Market Report Overview

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

The SARS – drugs in development research report provides a comprehensive overview on the therapeutics under development for SARS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for SARS and features dormant and discontinued projects.

Key Targets in the SARS Pipeline Drugs Market

The key targets in the SARS pipeline drugs market are 2019 Novel corona Virus Spike Glycoprotein, Human SARS coronavirus Spike Glycoprotein, Middle East Respiratory Syndrome Coronavirus S Protein, Cytosolic Phospholipase A2, 2′-5′ Oligoadenylate Synthetase, 3C Like Proteinase, Cathepsin L1, Coagulation Factor XII, and Envelope Small Membrane Protein, Fatty Acid Synthase.

SARS Pipeline Drugs Market, by Targets

SARS Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the SARS Pipeline Drugs Market

The key mechanisms of action in the SARS pipeline drugs market are 2019 Novel corona Virus Spike Glycoprotein Inhibitor, Human SARS coronavirus Spike Glycoprotein Inhibitor, Middle East Respiratory Syndrome Coronavirus S Protein Inhibitor, Cytosolic Phospholipase A2 Inhibitor, 2′-5′ Oligoadenylate Synthetase Activator, 3C Like Proteinase Inhibitor, Cathepsin L1 Inhibitor, Coagulation Factor XII Inhibitor, Envelope Small Membrane Protein Inhibitor, Fatty Acid Synthase Inhibitor.

SARS Pipeline Drugs Market, by MoA

SARS Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

SARS Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the SARS pipeline drugs market are Intravenous, Nasal, Oral, Inhalational, Intradermal, Intramuscular, Subcutaneous, Intratumor, Ophthalmic, Parenteral, and Vaginal.

SARS Pipeline Drugs Market Analysis, by RoA

SARS Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the SARS Pipeline Drugs Market

The key molecule types in the SARS pipeline drugs market are Small Molecule, Subunit Vaccine, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Oligonucleotide, Recombinant Vector Vaccine, Antibody, Biologic, Cell Therapy among others.

SARS Pipeline Drugs Market, by Molecule Type

SARS Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the SARS Pipeline Drugs Market

The major companies in the SARS pipeline drugs market are Adagio Therapeutics Inc, Halo Therapeutics Ltd, AIkido Pharma Inc, AlphaVax Inc, Amide Technologies Inc, Autoimmune Technologies LLC, Biotron Ltd, BioVaxys Technology Corp, Calder Biosciences Inc, and Cidara Therapeutics Inc among others.

SARS Pipeline Drugs Market, by Major Companies

SARS Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

SARS Pipeline Drugs Market Overview

Key Targets 2019 Novel corona Virus Spike Glycoprotein, Human SARS coronavirus Spike Glycoprotein, Middle East Respiratory Syndrome Coronavirus S Protein, Cytosolic Phospholipase A2, 2′-5′ Oligoadenylate Synthetase, 3C Like Proteinase, Cathepsin L1, Coagulation Factor XII, Envelope Small Membrane Protein, Fatty Acid Synthase
Key Mechanisms of action 2019 Novel corona Virus Spike Glycoprotein Inhibitor, Human SARS coronavirus Spike Glycoprotein Inhibitor, Middle East Respiratory Syndrome Coronavirus S Protein Inhibitor, Cytosolic Phospholipase A2 Inhibitor, 2′-5′ Oligoadenylate Synthetase Activator, 3C Like Proteinase Inhibitor, Cathepsin L1 Inhibitor, Coagulation Factor XII Inhibitor, Envelope Small Membrane Protein Inhibitor, Fatty Acid Synthase Inhibitor
Key Routes of Administration Intravenous, Nasal, Oral, Inhalational, Intradermal, Intramuscular, Subcutaneous, Intratumor, Ophthalmic, Parenteral, and Vaginal
Key molecule types Small Molecule, Subunit Vaccine, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Oligonucleotide, Recombinant Vector Vaccine, Antibody, Biologic, Cell Therapy
Major companies Adagio Therapeutics Inc, Halo Therapeutics Ltd, AIkido Pharma Inc, AlphaVax Inc, Amide Technologies Inc, Autoimmune Technologies LLC, Biotron Ltd, BioVaxys Technology Corp, Calder Biosciences Inc, and Cidara Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of SARS
  • The pipeline guide reviews pipeline therapeutics for SARS by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in SARS therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates SARS therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for SARS

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for SARS

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding SARS pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Adagio Therapeutics Inc
AIkido Pharma Inc
AlphaVax Inc
Amide Technologies Inc
Autoimmune Technologies LLC
Biotron Ltd
BioVaxys Technology Corp
Calder Biosciences Inc
Cidara Therapeutics Inc
Citospin SL
Cloud Pharmaceuticals Inc
Cocrystal Pharma Inc
ConserV Bioscience Ltd
CSL Ltd
Fab’entech SA
Global BioLife Inc Ltd
Halo Therapeutics Ltd
Hinge Bio Inc
Immodulon Therapeutics Ltd
Immune Biosolutions Inc
Lattice Biologics Ltd
Merck & Co Inc
Merck KGaA
Novavax Inc
Oncolys BioPharma Inc
Oncovir Inc
Phelix Therapeutics LLC
Pulmotect Inc
Sagimet Biosciences Inc
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
Theravectys SA
Trimunocor Ltd
Valo Therapeutics Oy
VBI Vaccines Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Severe Acute Respiratory Syndrome (SARS) – Overview

Severe Acute Respiratory Syndrome (SARS) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Severe Acute Respiratory Syndrome (SARS) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Severe Acute Respiratory Syndrome (SARS) – Companies Involved in Therapeutics Development

Severe Acute Respiratory Syndrome (SARS) – Drug Profiles

Severe Acute Respiratory Syndrome (SARS) – Dormant Projects

Severe Acute Respiratory Syndrome (SARS) – Product Development Milestones

Featured News & Press Releases

Apr 05, 2022: VBI Vaccines provides new data on VBI-2901

Mar 31, 2022: Adagio’s antibody meets primary endpoints in Phase II/III Covid-19 trials

Mar 17, 2022: BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus program in collaboration with The Ohio State University

Mar 01, 2022: Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Dec 22, 2021: Cocrystal Pharma’s COVID-19 oral and intranasal/pulmonary protease inhibitors exhibit powerful in vitro potency against the SARS-CoV-2 Omicron variant

Dec 16, 2021: Merck and Ridgeback announce publication of phase 3 study of Molnupiravir, an investigational oral antiviral COVID-19 treatment, in the New England Journal of Medicine

Oct 04, 2021: Merck-Ridgeback’s oral drug lowers hospitalisation risk in Covid-19 trial

Sep 30, 2021: Adagio’s ADG20 demonstrates benefit in Covid-19 clinical programme

Sep 24, 2021: A new oral antiviral drug for COVID is being tested in humans

Jul 26, 2021: Announcement of the effect of OBP-2011 against Indian and South African variants of SARS-CoV-2 virus

Jul 19, 2021: Announcement of manufacturing partnership on OBP-2011, an investigational product for COVID-19

Jun 21, 2021: Starpharma provides update on VIRALEZE UK

Jun 14, 2021: Announcement of the effect of OBP-2011 against SARS and MERS

Jun 01, 2021: Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Apr 19, 2021: NIH study finds antiviral drug effective against Covid-19

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Adagio Therapeutics Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by AIkido Pharma Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by AlphaVax Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Amide Technologies Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Autoimmune Technologies LLC, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Biotron Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by BioVaxys Technology Corp, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Calder Biosciences Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Cidara Therapeutics Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Citospin SL, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Cloud Pharmaceuticals Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Cocrystal Pharma Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by ConserV Bioscience Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by CSL Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Fab’entech SA, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Global BioLife Inc Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Halo Therapeutics Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Hinge Bio Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Immodulon Therapeutics Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Immune Biosolutions Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Lattice Biologics Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Merck & Co Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Merck KGaA, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Novavax Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Oncolys BioPharma Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Oncovir Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Phelix Therapeutics LLC, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Pulmotect Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Sagimet Biosciences Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Sorrento Therapeutics Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Starpharma Holdings Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Theravectys SA, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Trimunocor Ltd, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Valo Therapeutics Oy, 2022

Severe Acute Respiratory Syndrome (SARS) – Pipeline by VBI Vaccines Inc, 2022

Severe Acute Respiratory Syndrome (SARS) – Dormant Projects, 2022

Severe Acute Respiratory Syndrome (SARS) – Dormant Projects, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the SARS pipeline drugs market?

    The key targets in the SARS pipeline drugs market are 2019 Novel corona Virus Spike Glycoprotein, Human SARS coronavirus Spike Glycoprotein, Middle East Respiratory Syndrome Coronavirus S Protein, Cytosolic Phospholipase A2, 2′-5′ Oligoadenylate Synthetase, 3C Like Proteinase, Cathepsin L1, Coagulation Factor XII, Envelope Small Membrane Protein, Fatty Acid Synthase.

  • What are the key mechanisms of action in the SARS pipeline drugs market?

    The key mechanisms of action in the SARS pipeline drugs market are 2019 Novel corona Virus Spike Glycoprotein Inhibitor, Human SARS coronavirus Spike Glycoprotein Inhibitor, Middle East Respiratory Syndrome Coronavirus S Protein Inhibitor, Cytosolic Phospholipase A2 Inhibitor, 2′-5′ Oligoadenylate Synthetase Activator, 3C Like Proteinase Inhibitor, Cathepsin L1 Inhibitor, Coagulation Factor XII Inhibitor, Envelope Small Membrane Protein Inhibitor, Fatty Acid Synthase Inhibitor.

  • What are the key routes of administration in the SARS pipeline drugs market?

    The key routes of administration in the SARS pipeline drugs market are Intravenous, Nasal, Oral, Inhalational, Intradermal, Intramuscular, Subcutaneous, Intratumor, Ophthalmic, Parenteral, and Vaginal.

  • What are the key molecule types in the SARS pipeline drugs market?

    The key molecule types in the SARS pipeline drugs market are Small Molecule, Subunit Vaccine, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Oligonucleotide, Recombinant Vector Vaccine, Antibody, Biologic, and Cell Therapy.

  • What are the major companies in the SARS pipeline drugs market?

    The major companies in the SARS pipeline drugs market are Adagio Therapeutics Inc, Halo Therapeutics Ltd, AIkido Pharma Inc, AlphaVax Inc, Amide Technologies Inc, Autoimmune Technologies LLC, Biotron Ltd, BioVaxys Technology Corp, Calder Biosciences Inc, and Cidara Therapeutics Inc.

Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more